Gin & Co.
Gin & Co., licence 80067601: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Kygeia Naturals Inc.
- NPN or DIN-HM
- 80067601
- Status
- Active licence
- Licence date
- 10 March 2016
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Ginkgo biloba Source : Feuille Extract : Matériel brut sec Extraction ratio : 50:1 Dry plant equivalent : 1750 mg Potency : 24.0 % Flavonoid glycosides | 35.0 mg | Not calculated |
| Ginkgo biloba Source : Feuille Potency : 6.0 % Terpene lactones | Not specified | Not calculated |
| 2,5-Cyclohexadiène-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-décaméthyl-2,6,10,14,18,22,26,30,34,38-tétracontadécaényl]-5,6-diméthoxy-3-méthyl Source : Coenzyme Q10 | 75.0 mg | Not calculated |
Non-medicinal ingredients
Hydroxypropylméthylcellulose, Maltodextrine, Eau purifiée, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 1.0 Capsule | minimum: 2.0 Tous les jours ; maximum: 3.0 Tous les jours |
Uses authorised in Canada
Helps to maintain and/or support cardiovascular health. Helps to reduce the frequency of migraine headaches and associated nausea and vomiting when taken as a prophylactic. An antioxidant for the maintenance of good health. Helps to enhance cognitive function in adults. Helps to enhance memory in adults. Helps to support peripheral circulation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are taking health products that affect blood coagulation (e.g. blood thinners, clotting factor replacements, acetylsalicylic acid, ibuprofen, fish oils, vitamin E) as this may increase the risk of spontaneous bleeding.
- Précautions et mises en garde
Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you are taking medications for diabetes, blood pressure, blood thinners, or seizures. Migraine prophylaxis: Consult a health care practitioner if migraine frequency increases, and associated nausea and vomiting persist or worsen.
Source
Official Health Canada record, licence 80067601
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.